Review Article
Adenosine Deaminase in Cancer Research: Mechanisms and Therapeutic Targeting
Adenosine deaminase (ADA) is emerging as a central regulator of the tumor microenvironment, controlling extracellular adenosine levels that drive immunosuppression and tumor progression. This review examines the mechanistic roles of ADA and ADA2 in cancer biology, evaluates therapeutic strategies including enzyme replacement and small-molecule inhibition, and discusses practical considerations for researchers studying adenosine signaling in oncology.
The Adenosine Pathway in Tumor Immunity
Adenosine is a purine nucleoside that accumulates in the tumor microenvironment at concentrations far exceeding those found in normal tissues. This accumulation results from the sequential dephosphorylation of ATP released by dying tumor cells, hypoxia, and inflammatory stress. Once present in the extracellular space, adenosine engages four G protein-coupled receptors—A1, A2A, A2B, and A3—on immune cells, tumor cells, and stromal populations. Signaling through these receptors, particularly A2A and A2B, suppresses effector T cell function, promotes regulatory T cell expansion, and polarizes macrophages toward an immunosuppressive phenotype. The net effect is a tumor-permissive milieu in which antitumor immunity is blunted and cancer cells can evade immune surveillance.
Adenosine deaminase (ADA) is the principal enzyme responsible for the irreversible deamination of adenosine to inosine. By converting adenosine to inosine, ADA limits the availability of the ligand for adenosine receptors and thereby dampens adenosinergic signaling. In cancer, the balance between adenosine production—driven by CD39 and CD73 ectonucleotidases—and adenosine degradation—mediated by ADA—determines the local adenosine tone. When ADA activity is low or when the enzyme is sequestered in intracellular compartments, extracellular adenosine accumulates and reinforces immune evasion. Conversely, strategies that restore or augment ADA activity in the tumor microenvironment can reduce adenosine concentrations and relieve immunosuppression.
The adenosinergic machinery is expressed across multiple cell types within tumors, including cancer cells, infiltrating lymphocytes, myeloid cells, and endothelial cells. This complexity means that the net adenosine concentration at any given site reflects the integrated activity of numerous enzymes and transporters. Recent reviews have emphasized that the tumor adenosinergic system must be understood as an interconnected network rather than a linear pathway, with ADA serving as a critical node that links extracellular adenosine metabolism to intracellular purine salvage. Understanding this network is essential for designing rational therapeutic interventions that target adenosine signaling without disrupting systemic purine homeostasis.
For cancer researchers, the adenosine pathway offers a compelling target because it intersects with multiple hallmarks of cancer, including immune evasion, angiogenesis, and metastasis. The clinical relevance of this pathway is underscored by the development of CD73 inhibitors and A2A receptor antagonists, several of which have entered clinical trials. However, the role of ADA in this context has historically received less attention than the enzymes that produce adenosine. This review highlights the emerging evidence that ADA and its extracellular isoform ADA2 are not merely housekeeping enzymes but active participants in tumor immunity and promising therapeutic targets.
Adenosine Accumulation in Tumors
Extracellular adenosine accumulates in the tumor microenvironment through the coordinated action of CD39 and CD73, which convert ATP released from dying cells into adenosine. High adenosine concentrations suppress antitumor immunity by engaging A2A and A2B receptors on immune cells.
- ATP released from necrotic and stressed tumor cells feeds the adenosinergic cascade
- CD39 converts ATP to AMP; CD73 converts AMP to adenosine
- A2A receptor signaling inhibits T cell receptor-mediated activation
- A2B receptor activation promotes myeloid-derived suppressor cell function
ADA-Mediated Adenosine Degradation
Adenosine deaminase catalyzes the deamination of adenosine to inosine, effectively removing the ligand for adenosine receptors. This reaction represents the primary catabolic route for extracellular adenosine and a natural brake on adenosinergic signaling.
- ADA converts adenosine to inosine irreversibly
- Inosine does not activate adenosine receptors with comparable potency
- ADA activity reduces the immunosuppressive adenosine tone
- Intracellular ADA regulates the purine salvage pathway
ADA in Cancer Prognosis
Genetic and expression studies have linked ADA to clinical outcomes in several cancer types. Systematic analyses have explored the association of adenosine deaminase with esophageal cancer from a genetic perspective, suggesting that ADA variants or expression levels may influence disease susceptibility or progression.
- ADA expression varies across tumor types and stages
- Genetic polymorphisms in ADA may modulate cancer risk
- ADA levels in serum or tumor tissue may serve as biomarkers
- ADA status could inform patient stratification for adenosinergic therapies
ADA in the Tumor Microenvironment
The tumor microenvironment is characterized by metabolic dysregulation, hypoxia, and chronic inflammation, all of which influence adenosine metabolism. Extracellular adenosine in tumors can suppress immune responses and promote tumor growth, creating a self-reinforcing cycle of immune evasion and cancer progression. Adenosine deaminase 2 (ADA2) is a secreted isoform of ADA that converts adenosine into inosine in the extracellular space. Unlike the intracellular ADA1, ADA2 is released by monocytes and macrophages and is thought to be the dominant ADA activity in plasma and tissue fluids. The presence of ADA2 in the tumor microenvironment suggests that it may play a role in regulating local adenosine concentrations and, consequently, the intensity of adenosinergic signaling.
The balance between adenosine production and degradation is a critical determinant of immune function within tumors. When adenosine accumulates, it engages A2A receptors on T cells and natural killer cells, leading to the activation of protein kinase A and the suppression of effector functions. Adenosine also promotes the differentiation of regulatory T cells and the expansion of myeloid-derived suppressor cells, further skewing the immune landscape toward tolerance. By degrading adenosine, ADA2 can interrupt this cascade and restore the capacity of immune cells to mount antitumor responses. Preclinical studies have demonstrated that recombinant ADA2 can inhibit tumor growth in an enzyme activity-dependent manner, providing direct evidence that adenosine degradation is a viable therapeutic strategy.
The cellular sources of ADA and ADA2 in tumors are an area of active investigation. Tumor cells themselves may express ADA, and its expression level can vary depending on the tissue of origin and the genetic background of the tumor. Infiltrating immune cells, particularly macrophages, are a major source of ADA2. The relative contribution of tumor-derived versus immune-derived ADA to the overall adenosine-degrading capacity of the tumor microenvironment remains to be fully defined. However, the observation that ADA2 is elevated in the plasma of cancer patients suggests that systemic adenosine metabolism may also be altered in malignancy, with potential implications for immune function throughout the body.
From a therapeutic perspective, the tumor microenvironment presents both opportunities and challenges for ADA-based interventions. On one hand, the extracellular location of adenosine makes it accessible to systemically administered enzymes. On the other hand, the tumor microenvironment is characterized by hypoxia, acidic pH, and the presence of proteases, all of which can affect enzyme stability and activity. Engineering ADA variants with improved stability, catalytic efficiency, and resistance to inactivation is therefore a priority for the field. Advances in protein engineering and formulation are enabling the development of ADA-based therapeutics that can withstand the harsh conditions of the tumor microenvironment and maintain sustained adenosine-degrading activity.
| Enzyme | Localization | Primary Function | Cancer Relevance |
|---|---|---|---|
| ADA1 | Intracellular (cytosol) | Purine metabolism; deamination of adenosine and deoxyadenosine | Regulates intracellular adenosine pools; genetic variants linked to cancer susceptibility |
| ADA2 | Extracellular (secreted) | Deamination of extracellular adenosine to inosine | Dominant ADA activity in plasma; modulates tumor microenvironment adenosine tone |
| CD39 | Cell surface (ecto) | Hydrolysis of ATP/ADP to AMP | Rate-limiting step in adenosine production; upregulated in tumors |
| CD73 | Cell surface (ecto) | Hydrolysis of AMP to adenosine | Key adenosine-producing enzyme; target of multiple clinical-stage inhibitors |
ADA as a Therapeutic Target
The central role of adenosine in tumor immune evasion has made the adenosinergic pathway an attractive target for cancer therapy. While much of the drug development effort has focused on blocking adenosine production (CD73 inhibitors) or adenosine receptor signaling (A2A/A2B antagonists), there is growing interest in strategies that enhance adenosine degradation. Adenosine deaminase therapy represents a conceptually distinct approach: rather than preventing adenosine from being made or from binding to its receptors, ADA-based therapeutics actively remove adenosine from the tumor microenvironment. This approach has the advantage of addressing the root cause of adenosinergic immunosuppression—the accumulation of adenosine itself.
Recombinant ADA has been developed as an enzyme replacement therapy for severe combined immunodeficiency (SCID) caused by ADA deficiency, demonstrating the feasibility of systemic ADA administration in humans. In the cancer context, the goal is not to replace a missing enzyme but to augment adenosine degradation in the tumor microenvironment. Preclinical studies have shown that PEGylated ADA2 (PEGADA2) inhibits tumor growth by targeting adenosine in an enzyme activity-dependent manner and thereby modulating immune responses. These findings provide proof-of-concept that exogenous ADA can exert antitumor activity by relieving adenosine-mediated immunosuppression.
In addition to enzyme replacement, small-molecule inhibitors of ADA have been explored as therapeutic agents. The rationale for ADA inhibition in cancer is less intuitive than for ADA supplementation, but it is based on the observation that ADA is required for the proliferation of certain cancer cells. In some tumor types, ADA activity supports the salvage of purines needed for DNA synthesis, and inhibiting ADA can deprive cancer cells of essential nucleotides. However, the use of ADA inhibitors in oncology is complicated by the dual role of ADA in both promoting and suppressing tumor growth, depending on the cellular context. The decision to inhibit or augment ADA activity must therefore be guided by a detailed understanding of the specific tumor type and its metabolic dependencies.
The catalytic mechanism of ADA has been studied in detail, providing a foundation for the rational design of both inhibitors and enzyme variants with altered properties. Detailed knowledge of the catalytic mechanism is of high significance in drug design, as it enables the prediction of how mutations or chemical modifications will affect enzyme activity. For therapeutic applications, engineered ADA variants may be designed to have increased catalytic efficiency, altered substrate specificity, or improved pharmacokinetic properties. The ability to produce recombinant ADA with defined characteristics is essential for both research and clinical applications, and advances in enzyme engineering are expanding the toolkit available to investigators.
Assess Adenosine Tone
Quantify adenosine concentrations in tumor tissue or plasma using mass spectrometry or enzymatic assays. Determine the expression of CD39, CD73, ADA1, and ADA2 to establish the adenosinergic profile of the tumor.
Select Therapeutic Strategy
Choose between ADA supplementation (to degrade adenosine) or ADA inhibition (to block purine salvage) based on the tumor type and its metabolic dependencies. Consider combination with checkpoint inhibitors or other immunotherapies.
Engineer or Source the Enzyme
For supplementation strategies, obtain recombinant ADA or ADA2 with appropriate purity, activity, and stability. For inhibition strategies, select a small-molecule inhibitor with suitable potency and selectivity.
Validate in Preclinical Models
Test the therapeutic approach in syngeneic mouse tumor models or patient-derived xenografts. Monitor tumor growth, immune cell infiltration, and adenosine levels to confirm the mechanism of action.
Research Tools for Adenosine Signaling
Studying adenosine signaling in cancer requires a suite of research tools that enable the quantification of adenosine and its metabolites, the manipulation of ADA activity, and the assessment of downstream signaling events. Recombinant ADA is a key reagent for these studies, as it can be used to deplete adenosine from culture media or biological samples, allowing researchers to investigate the effects of adenosine removal on cellular phenotypes. Recombinant ADA can also be used to generate adenosine-free conditions for studying adenosine receptor signaling in vitro, providing a clean system for dissecting the contributions of individual receptor subtypes.
The production of high-quality recombinant ADA is a specialized undertaking that requires expertise in enzyme expression, purification, and characterization. Researchers may choose to produce ADA in-house or to source it from commercial suppliers. When selecting a source of recombinant ADA, it is important to consider the enzyme's specific activity, purity, endotoxin levels, and batch-to-batch consistency. For in vivo studies, the enzyme may need to be formulated for sustained activity, for example through PEGylation or encapsulation. The choice of expression system—bacterial, yeast, or mammalian—can also affect the post-translational modifications and folding of the enzyme, which in turn influence its activity and stability.
In addition to recombinant ADA, researchers studying adenosine signaling have access to a range of other tools, including adenosine receptor antagonists, CD73 inhibitors, and antibodies against adenosinergic enzymes. These tools can be used in combination to dissect the contributions of different components of the pathway. For example, a researcher might use a CD73 inhibitor to block adenosine production and recombinant ADA to enhance adenosine degradation, thereby testing whether the combined approach is more effective at relieving immunosuppression than either intervention alone. The availability of well-characterized reagents is critical for the reproducibility and interpretability of such experiments.
For researchers developing ADA-based diagnostics or therapeutics, access to professional enzyme development services can accelerate the path from concept to application. Services such as enzyme expression and purification, directed evolution and mutant library screening, and thermostability and pH tolerance engineering can help optimize ADA variants for specific applications. Similarly, enzyme engineering for CDx purity, stability, and performance can support the development of companion diagnostics that measure ADA activity or adenosine levels in patient samples. These capabilities enable researchers to move beyond off-the-shelf reagents and develop custom tools tailored to their specific experimental needs.
Recombinant ADA
Recombinant human ADA is available for in vitro and in vivo studies. It can be used to deplete adenosine from culture media, generate adenosine-free conditions, or test the therapeutic potential of adenosine degradation.
- Available in multiple formats (lyophilized, solution, PEGylated)
- Activity verified by enzymatic assay
- Low endotoxin for cell culture and in vivo use
- Can be used in combination with adenosine receptor antagonists
Adenosine Quantification
Accurate measurement of adenosine concentrations is essential for studying the adenosinergic pathway. Mass spectrometry-based methods provide the most sensitive and specific quantification of adenosine and its metabolites.
- LC-MS/MS for high sensitivity and specificity
- Enzymatic assays for high-throughput screening
- Fluorescent probes for real-time imaging
- Sample preparation is critical for accurate results
Enzyme Development Support
For researchers developing ADA-based tools or therapeutics, professional enzyme development services can provide support with expression, purification, engineering, and formulation.
- Recombinant expression in multiple systems
- Site-directed mutagenesis and directed evolution
- Biophysical characterization and stability testing
- Scale-up and technology transfer
ADA in Leukemia and Solid Tumors
The role of ADA in cancer has been studied most extensively in hematologic malignancies, where ADA deficiency is associated with severe combined immunodeficiency and where ADA inhibitors have been explored as chemotherapeutic agents. In leukemia, ADA activity is often elevated in malignant cells, reflecting their high proliferative rate and increased demand for purines. Inhibiting ADA in this context can deplete the nucleotide pools required for DNA synthesis, leading to cell death. However, the clinical use of ADA inhibitors such as pentostatin has been limited by toxicity and by the development of resistance. A more nuanced understanding of ADA's role in leukemia is needed to identify patient populations that are most likely to benefit from ADA-targeted therapies.
In solid tumors, the role of ADA is more complex and context-dependent. On one hand, ADA expression in tumor cells may support proliferation by facilitating purine salvage. On the other hand, ADA activity in the tumor microenvironment can degrade adenosine and relieve immunosuppression, which would be expected to inhibit tumor growth. The net effect of ADA on tumor progression therefore depends on the balance between these opposing activities. Recent studies have begun to dissect this complexity, revealing that the cellular source of ADA and its localization (intracellular versus extracellular) are critical determinants of its impact on tumor biology.
Esophageal cancer is one tumor type in which the association of ADA with clinical outcomes has been systematically investigated. Genetic studies have explored the association of adenosine deaminase with esophageal cancer from a genetic perspective, examining whether ADA variants influence susceptibility or prognosis. These studies suggest that ADA may play a role in esophageal cancer pathogenesis, although the underlying mechanisms remain to be fully elucidated. The findings highlight the potential of ADA as a biomarker for risk stratification and as a target for therapeutic intervention in this disease.
Immunotherapy resistance is a major challenge in oncology, and the adenosine pathway has been implicated as a mechanism of resistance to immune checkpoint inhibitors. Tumors that upregulate adenosine production or downregulate adenosine degradation may be able to evade the antitumor immune responses unleashed by checkpoint blockade. In this context, ADA-based therapies could be used to sensitize tumors to checkpoint inhibitors by reducing adenosine-mediated immunosuppression. Preclinical studies combining ADA with checkpoint inhibitors are needed to test this hypothesis and to identify the optimal sequencing and dosing of these agents.
Leukemia
ADA activity is elevated in many leukemias, supporting purine salvage and rapid proliferation. ADA inhibitors have been explored as chemotherapeutic agents, but their use is limited by toxicity and resistance.
- ADA inhibitors deplete nucleotide pools required for DNA synthesis
- Pentostatin is a potent ADA inhibitor used in hairy cell leukemia
- Resistance to ADA inhibitors can develop through multiple mechanisms
- ADA expression may serve as a biomarker for treatment response
Esophageal Cancer
Genetic studies have linked ADA to esophageal cancer susceptibility and prognosis. The role of ADA in this disease may involve both tumor cell-intrinsic effects and modulation of the immune microenvironment.
- ADA variants may influence esophageal cancer risk
- ADA expression in tumor tissue may correlate with clinical outcomes
- ADA2 from macrophages may regulate adenosine in the tumor microenvironment
- ADA status could inform patient selection for adenosinergic therapies
Checkpoint Inhibitor Resistance
Adenosine accumulation has been proposed as a mechanism of resistance to immune checkpoint inhibitors. ADA-based therapies that degrade adenosine may restore sensitivity to checkpoint blockade.
- Adenosine suppresses effector T cell function, counteracting checkpoint inhibitor activity
- Combining ADA with anti-PD-1/PD-L1 may enhance antitumor immunity
- Biomarkers of adenosine tone could predict response to combination therapy
- Preclinical studies are needed to optimize combination regimens
Future Directions and Combinatorial Strategies
The future of ADA-based cancer therapy lies in the rational combination of adenosine modulation with other treatment modalities. Immune checkpoint inhibitors have revolutionized cancer treatment, but a substantial proportion of patients do not respond or develop resistance. The adenosine pathway represents a complementary target that could enhance the efficacy of checkpoint blockade by relieving a key immunosuppressive mechanism. Preclinical studies combining ADA with anti-PD-1 or anti-PD-L1 antibodies are needed to establish the scientific rationale for clinical trials and to identify biomarkers that predict response.
Beyond checkpoint inhibitors, ADA-based therapies could be combined with other immunomodulatory agents, including agonists of costimulatory receptors, cytokines, and adoptive cell therapies. The optimal combination will depend on the tumor type, the baseline adenosine tone, and the immune landscape of the tumor. Personalized approaches that measure adenosine levels and ADA activity in individual patients could guide the selection of combination partners and the sequencing of treatments. The development of companion diagnostics that quantify adenosinergic biomarkers is therefore a priority for the field.
Advances in protein engineering are expanding the possibilities for ADA-based therapeutics. Engineered ADA variants with improved catalytic efficiency, stability, and pharmacokinetic properties could enhance the efficacy of enzyme replacement therapy. Directed evolution and rational design approaches can be used to optimize ADA for specific applications, such as resistance to proteases in the tumor microenvironment or enhanced activity at the acidic pH found in tumors. The ability to produce these engineered enzymes at scale with consistent quality is essential for their translation to the clinic.
The integration of ADA-based approaches with emerging technologies, such as cell therapy and gene therapy, offers additional opportunities. Engineered human cells that secrete ADA could provide a continuous source of adenosine-degrading activity within the tumor microenvironment. This cell-based approach could overcome the pharmacokinetic limitations of systemically administered enzymes and provide localized adenosine degradation at the site of the tumor. The development of such cell-based therapies requires expertise in cell engineering, enzyme expression, and formulation, and represents an exciting frontier in cancer immunotherapy.
Practical Considerations for Researchers
For cancer researchers seeking to study adenosine signaling or develop ADA-based therapies, several practical considerations should guide experimental design. First, the choice of ADA reagent is critical. Recombinant ADA is available from multiple commercial sources, but the quality and activity of these preparations can vary significantly. Researchers should verify the specific activity, purity, and endotoxin levels of each lot and should consider whether the enzyme is suitable for the intended application, whether that be cell culture, in vivo administration, or diagnostic assay development.
Second, the experimental model system must be chosen carefully. In vitro models using cancer cell lines or primary immune cells can provide mechanistic insights, but they may not recapitulate the complex interactions of the tumor microenvironment. Syngeneic mouse tumor models are valuable for studying the effects of ADA on antitumor immunity, as they allow for the assessment of immune cell infiltration and function in the context of an intact immune system. Patient-derived xenografts can be used to study the effects of ADA on human tumor cells, but they lack a functional immune system and are therefore less suitable for studying immunomodulatory effects.
Third, the quantification of adenosine and its metabolites is essential for interpreting the effects of ADA modulation. Mass spectrometry-based methods provide the most accurate and comprehensive analysis of the adenosinergic metabolome, but they require specialized equipment and expertise. Enzymatic assays and fluorescent probes offer simpler alternatives for high-throughput screening, but they may have lower sensitivity or specificity. Researchers should choose the analytical method that best matches their experimental needs and should validate the method in their specific sample matrix.
Finally, researchers developing ADA-based diagnostics or therapeutics should consider engaging professional services for enzyme development and characterization. Services such as enzyme expression and purification, enzyme engineering and modification, and high-purity diagnostic enzyme scale-up and technology transfer can provide the specialized expertise and infrastructure needed to advance a project from the research bench to clinical application. These services can help ensure that the enzyme product meets the required specifications for purity, activity, and stability, and can support the development of companion diagnostics that measure ADA activity or adenosine levels in patient samples.
FAQ
What is the role of adenosine deaminase in cancer?
Adenosine deaminase (ADA) catalyzes the conversion of adenosine to inosine, thereby regulating the concentration of adenosine in the tumor microenvironment. High adenosine levels suppress antitumor immunity by engaging A2A and A2B receptors on immune cells. By degrading adenosine, ADA can relieve this immunosuppression and potentially inhibit tumor growth. However, ADA also supports purine salvage in cancer cells, and its net effect on tumor progression depends on the cellular context and localization.
How does ADA2 differ from ADA1 in cancer biology?
ADA1 is primarily an intracellular enzyme involved in purine metabolism, while ADA2 is a secreted enzyme that degrades extracellular adenosine. In the tumor microenvironment, ADA2 is thought to be the dominant adenosine-degrading activity in plasma and tissue fluids. Preclinical studies have shown that PEGylated ADA2 can inhibit tumor growth in an enzyme activity-dependent manner, highlighting the therapeutic potential of targeting extracellular adenosine.
What are the therapeutic strategies targeting ADA in cancer?
Two main strategies are being explored: enzyme replacement therapy, which involves administering recombinant ADA or ADA2 to degrade adenosine in the tumor microenvironment, and ADA inhibition, which aims to block purine salvage in cancer cells. The choice of strategy depends on the tumor type and its metabolic dependencies. Enzyme replacement is generally considered more promising for relieving adenosine-mediated immunosuppression.
How can researchers study adenosine signaling in cancer?
Researchers can study adenosine signaling using a combination of tools, including recombinant ADA to deplete adenosine, adenosine receptor antagonists to block signaling, CD73 inhibitors to block adenosine production, and mass spectrometry to quantify adenosine and its metabolites. The choice of tools depends on the specific research question and the experimental model system.
References
- The progress and prospects of targeting the adenosine pathway in cancer. Biomark Res. 2025;13:45. View article View article. View article. View article
- Adenosine deaminase 1 overexpression enhances the antitumor immune response. Front Immunol. 2022;13:890456. View article View article. View article. View article
- The adenosinergic machinery in cancer: in-tandem insights from basic mechanisms to therapy. Front Immunol. 2023;14:1111369. View article View article. View article. View article
- Exploring the role of adenosine deaminase in esophageal .. This study aims to systematically elucidate the association of adenosine deaminase with esophageal cancer from a genetic perspective and explore its potential ... View article
- Exploring the role of adenosine deaminase in esophageal .. This study aims to systematically elucidate the association of adenosine deaminase with esophageal cancer from a genetic perspective and explore its potential ... View article
Advance Your Adenosine Research
Access high-quality recombinant ADA and specialized enzyme development services to accelerate your cancer research. Our team supports researchers with enzyme expression, purification, engineering, and characterization for adenosine signaling studies.